FATE (Fate Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

FATE (Fate Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

FATEFate Therapeutics, Inc.

Mkt Cap$158M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$7M

Net Income (TTM)-$136M

EPS (TTM)-$1.15

Free Cash Flow (TTM)-$112M

Gross Margin-94.1%

Op. Margin-2222.4%

Net Margin-2051.1%

FCF Margin-1685.8%

P/S Ratio (TTM)23.7x

P/E Ratio (TTM)—

YoY Rev Growth-51.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$59M	-$7M	-$29M
Q2 23	$933K	-$40M	-$63M
Q3 23	$2M	-$3M	-$51M
Q4 23	$2M	-$3M	-$48M
Q1 24	$2M	-$3M	-$51M
Q2 24	$7M	$2M	-$45M
Q3 24	$3M	$3M	-$52M
Q4 24	$2M	$2M	-$62M
Q1 25	$2M	$2M	-$41M
Q2 25	$2M	$2M	-$37M
Q3 25	$2M	$2M	-$35M
Q4 25	$1M	-$12M	-$35M

Valuation

Quarter	P/S	P/E
Q1 23	1.2x	—
Q2 23	1.3x	—
Q3 23	1.5x	—
Q4 23	2.5x	—
Q1 24	24.3x	—
Q2 24	12.8x	—
Q3 24	11.7x	—
Q4 24	11.6x	—
Q1 25	11.8x	—
Q2 25	18.6x	—
Q3 25	22.1x	—
Q4 25	23.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$29M	-$32M
Q2 23	-$28M	-$31M
Q3 23	-$38M	-$39M
Q4 23	-$37M	-$37M
Q1 24	-$33M	-$33M
Q2 24	-$32M	-$32M
Q3 24	-$29M	-$30M
Q4 24	-$28M	-$28M
Q1 25	-$34M	-$35M
Q2 25	-$25M	-$26M
Q3 25	-$24M	-$27M
Q4 25	-$23M	-$25M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$3M
Q2 23	$2M
Q3 23	$565K
Q4 23	$181K
Q1 24	$86K
Q2 24	$51K
Q3 24	$495K
Q4 24	$98K
Q1 25	$1M
Q2 25	$1M
Q3 25	$2M
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+220.3%	-5.7%
Q2 23	-95.0%	-37.5%
Q3 23	-87.0%	-47.5%
Q4 23	-96.2%	-54.3%
Q1 24	-96.7%	-39.5%
Q2 24	+625.8%	-18.3%
Q3 24	+58.1%	+4.2%
Q4 24	+11.0%	+27.9%
Q1 25	-15.4%	-19.0%
Q2 25	-71.8%	-25.0%
Q3 25	-43.4%	-34.2%
Q4 25	-26.4%	-43.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$11M	18.6%
Q2 23	$0	0.0%
Q3 23	$10M	519.8%
Q4 23	$0	0.0%
Q1 24	$11M	570.4%
Q2 24	$10M	142.2%
Q3 24	$12M	382.7%
Q4 24	$9M	490.3%
Q1 25	$7M	453.1%
Q2 25	$7M	375.1%
Q3 25	$5M	279.2%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$66M	$22M
Q2 23	$41M	$23M
Q3 23	$34M	$19M
Q4 23	$32M	$18M
Q1 24	$32M	$21M
Q2 24	$35M	$17M
Q3 24	$35M	$21M
Q4 24	$34M	$15M
Q1 25	$29M	$14M
Q2 25	$27M	$11M
Q3 25	$26M	$11M
Q4 25	$25M	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$42M	$367M	$409M
Q2 23	$47M	$331M	$378M
Q3 23	$33M	$316M	$350M
Q4 23	$42M	$273M	$315M
Q1 24	$121M	$262M	$384M
Q2 24	$37M	$268M	$305M
Q3 24	$38M	$259M	$297M
Q4 24	$36M	$243M	$279M
Q1 25	$45M	$196M	$240M
Q2 25	$41M	$182M	$223M
Q3 25	$41M	$175M	$215M
Q4 25	$47M	$157M	$204M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	98M	+0.9%
Q2 23	98M	+0.4%
Q3 23	99M	+0.2%
Q4 23	99M	+0.0%
Q1 24	101M	+2.5%
Q2 24	117M	+16.2%
Q3 24	118M	+0.3%
Q4 24	118M	+0.0%
Q1 25	118M	+0.5%
Q2 25	119M	+0.1%
Q3 25	119M	+0.4%
Q4 25	119M	-0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	50
FY 15	$41K	60
FY 16	$67K	66
FY 17	$51K	80
FY 18	$46K	104
FY 19	$60K	178
FY 20	$113K	279
FY 21	$124K	449
FY 22	$175K	551
FY 23	$289K	220
FY 24	$75K	181
FY 25	$33	200K